Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03729453 · ClinicalTrials.gov registry record

Intra-operative Pancreatoscopy in Patients With IPMN

A clinical trial of Intraductal Papillary Mucinous Neoplasm, sponsored by Boston Scientific Corporation.

Active
Registry status
100
Enrollment target
8
Study locations

NCT03729453: Active study of Intraductal Papillary Mucinous Neoplasm, sponsored by Boston Scientific Corporation.

NCT03729453 is a study of Intraductal Papillary Mucinous Neoplasm that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 100 participants, below the 2,256-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03729453, a study of Intraductal Papillary Mucinous Neoplasm, is active but no longer recruiting, sponsored by Boston Scientific Corporation.

ACTIVE NOT RECRUITING
Registry status
100 participants
Enrollment target
8
Study locations

Study Summary

To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.

Primary Outcome

Rate of detection of discontinuous (skip) lesions along the main pancreatic duct of patients with IPMN using intraoperative pancreatoscopy based on visual impression of IPMN and/or pancreatoscopy guided biopsies

Interventions

  • DEVICE SpyGlass

Study Locations (8)

Other

  • The First Affiliated Hospital of Nanjing Medical University - Nanjing
  • Asian Institute of Gastroenterology - Hyderabad
  • Academic Medical Center - Amsterdam
  • University Hospital of UMEA - Umeå

Colorado

  • University of Colorado Hospital - Denver

Indiana

  • Indiana University Health - Indianapolis

Maryland

  • Johns Hopkins Hospital University - Baltimore

Osaka

  • Kansai Medical University - Hirakata

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2019-03-20
Est. Completion 2027-05
Boston Scientific Corporation

280 total trials

What the registry record for NCT03729453 still lists

NCT03729453 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,256-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Intraductal Papillary Mucinous Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which SpyGlass is the first listed.

NCT03729453 lists 8 locations in 5 states (Other, Colorado, Indiana).

Frequently Asked Questions

What is clinical trial NCT03729453 about?

NCT03729453 is a clinical study titled "Intra-operative Pancreatoscopy in Patients With IPMN". To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a ...

What is the current status of trial NCT03729453?

This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2019-03-20. Estimated completion is 2027-05.

What conditions does trial NCT03729453 study?

This clinical trial studies the following conditions: Intraductal Papillary Mucinous Neoplasm.

What interventions are being tested in trial NCT03729453?

The interventions under investigation include: SpyGlass (DEVICE).

Who is sponsoring clinical trial NCT03729453?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03729453 being conducted?

This trial has 8 study locations across Colorado, Indiana, Maryland, Osaka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intraductal Papillary Mucinous Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03729453, the US trial registry maintained by the National Library of Medicine. NCT03729453 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.